Daniel R Greenwald
Overview
Explore the profile of Daniel R Greenwald including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gershon A, Ma E, Xu T, Montez M, Naqvi K, Ku G, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Mar;
23(5):e222-e231.
PMID: 36925388
Background: Venetoclax in combination with hypomethylating agents (HMAs) is standard-of-care in patients with newly diagnosed acute myeloid leukemia (AML) who are ≥ 75 years old or unfit for intensive chemotherapy....
2.
Nastoupil L, Kuruvilla J, Chavez J, Bijou F, Witzig T, Santoro A, et al.
EJHaem
. 2022 Jul;
3(2):394-405.
PMID: 35846031
The multicenter, phase Ib CC-122-DLBCL-001 dose-expansion study (NCT02031419) explored the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC-122) plus rituximab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)...
3.
Sharman J, Farber C, Mahadevan D, Schreeder M, Brooks H, Kolibaba K, et al.
Br J Haematol
. 2016 Dec;
176(3):412-420.
PMID: 27982425
Ibrutinib is effective in patients with chronic lymphocytic leukaemia (CLL); however, treatment resistance remains a problem. Ublituximab is a novel, glycoengineered anti-CD20 monoclonal antibody with single-agent activity in relapsed CLL....
4.
Barr P, Saylors G, Spurgeon S, Cheson B, Greenwald D, OBrien S, et al.
Blood
. 2016 Mar;
127(20):2411-5.
PMID: 26968534
Although agents targeting B-cell receptor signaling have provided practice-changing results in relapsed chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), they require prolonged administration and provide incomplete responses. Given synergistic...
5.
Greenwald D, Li H, Luger S, Go R, King D, Patel T, et al.
J Hematol Oncol
. 2013 Jul;
6:46.
PMID: 23829878
Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II...
6.
Sugahara K, Teesalu T, Karmali P, Kotamraju V, Agemy L, Greenwald D, et al.
Science
. 2010 Apr;
328(5981):1031-5.
PMID: 20378772
Poor penetration of anticancer drugs into tumors can be an important factor limiting their efficacy. We studied mouse tumor models to show that a previously characterized tumor-penetrating peptide, iRGD, increased...